Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
drug combinations
Biotech
Boundless Bio lays off 33% of staff as lead program stumbles
Boundless has pivoted to a combination of two molecules that struggled as monotherapies after seeing phase 1/2 data on its lead candidate.
Nick Paul Taylor
May 27, 2025 8:40am
Immutep's LAG-3 agent posts 'impressive' survival data
May 5, 2025 10:37am
Lilly's oral SERD Ember counts on Verzenio to broaden its glow
Dec 11, 2024 8:15am
Vir keeps pressure on Gilead with midphase hepatitis D data
Jun 5, 2024 8:52am
Gilead-Arcus' TIGIT gets high response in gastric cancer
Nov 7, 2023 9:40am
Faron's latest snapshot suggests antibody has leukemia potential
Jul 19, 2023 8:45am
